- CSPC Pharma’s full year revenue missed estimates, coming in at 31.45 billion yuan instead of the estimated 31.84 billion yuan.
- The sales of finished drugs externally were 25.60 billion yuan, slightly under the estimated 25.88 billion yuan.
- The final dividend per share was 14 Hong Kong cents.
- The underlying profit was 6.28 billion yuan.
- The company’s stock was rated as ‘buy’ by 33 analysts, ‘hold’ by 3 analysts, and ‘sell’ by 1 analyst.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to the Smartkarma Smart Scores, CSPC Pharmaceutical Group has a positive long-term outlook. The company has received a score of 5 out of 5 for its dividend, indicating that it is a strong performer in terms of paying out dividends to its shareholders. This is good news for investors who are looking for stable and consistent returns on their investment.
In addition, CSPC Pharmaceutical Group has also received a score of 4 out of 5 for resilience, suggesting that the company is well-equipped to weather any potential challenges or market fluctuations. This is important for investors as it indicates that the company has a strong foundation and is able to withstand any potential risks.
Furthermore, CSPC Pharmaceutical Group has also received a score of 4 out of 5 for momentum, indicating that the company is performing well and is expected to continue its positive trajectory in the future. This is a promising sign for investors as it suggests that the company is on a path of growth and success.
Overall, based on its Smartkarma Smart Scores, CSPC Pharmaceutical Group is a strong and resilient company with a positive outlook for the long-term. With its focus on manufacturing and selling pharmaceutical products, as well as its involvement in the development of innovative drugs, the company is well-positioned to continue its success in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
